

# 감각신경성 난청의 치료

가톨릭대학교 의과대학 이비인후과학교실  
 전 범 조·여 상 원

## Treatment of Sensorineural Hearing Loss

Beom Cho Jun, MD and Sang-Won Yeo, MD

Department of Otolaryngology, The Catholic University, Seoul, Korea

### 서 론

2)

, 3)

, 4)

, 5)

1)

### 면역억제요법

### 면역성 난청의 치료

(Immune - mediated hearing loss)

가 가

가 ,  
 Kanzaki <sup>2)</sup> 1 prednisone 30 mg  
 3 5 mg 18~20

가

50%

. 1) 20~50 ( ),

2 McCabe<sup>3)</sup>  
 : , 137 - 701 505 (initial treatment) cyclophosphamide 60 mg  
 가 : (02) 590 - 1750, 2791 - : (02) 595 - 1354 12 , prednisone 30 mg 4  
 E - mail : swyeo@catholic.ac.kr 가 (



12 ( 13 )  
70% , 80%

8 methotrexate  
Matteson  
10) 17 가 15 dB  
methotrexate 12  
65% , 12%  
23% 가 . me-  
thotrexate  
(interstitial fibrosis)  
4 CBC,

**치료결과판정**

3  
가 20%  
good response ,  
Kanzaki 2) 가 ice - water  
caloric test

**돌발성 난청의 치료**

folic acid folate  
11)

**최신면역요법**

가  
oral tolerance therapy, (vaccination)  
tumor  
necrotic factor(TNF), intercellular adhesion mole-  
cule - 1(ICAM - 1), CD4 가,  
(multiple sclerosis) VLA - 4, gamma -  
interferon(IFN - ) 가

**부신피질호르몬제**

myelin basic protein(MBP) oral feeding  
T - transforming growth factor -  
beta(TGF - ) IFN - TNF  
, T - T -  
prednisone 60~80 mg(1 mg/kg/  
day) 10~12

12) Dalal 13)  
experimental allergic  
encephalitis(EAE) testosterone  
EAE , Yeo 14)  
testosterone  
. Testosterone 38%  
T - IL - 10  
가 Th1 down - regulate witz 16)

Wilson 15)  
90 dB  
placebo  
90 dB  
78%, placebo  
, Mosko-

:  
 Wilkins <sup>17)</sup> carbogen 가 1 carbo-  
 gen  
 Redleaf <sup>23)</sup> diatrizoate dextran  
 36 74%가  
**혈관 확장제 및 혈액순환 개선제**  
 가  
 가  
 Histamine 2.75 mg/day 500 ml  
 30 3  
 papaverine, nicotinic acid가 가  
 niacin, procain . Fisch <sup>18)</sup> novan<sup>24)</sup> . Schuknecht Do-  
 carbogen gas mixture(5% CO<sub>2</sub>, 95% O) 가 12 가  
 가 1  
 8 30 carbogen Wilson<sup>25)</sup> 70% herpes in-  
 . Donaldson<sup>19)</sup> fection  
 69.6% 가 latent herpes  
 66% , Rahko Kotti<sup>20)</sup> carbogen virus 가  
 heparin Acyclovir(Zovirax)가  
 DHA  
 . Acyclovir  
 low molecular weight 800 mg 1 5 10 . herpes  
 dextran, mannitol, pentoxifylline, heparin simplex type 1 2, cytomegalovirus, varicella-  
 가 . low molecular weight dextran zoster virus, E - B virus human herpes  
 virus valacyclovir가  
<sup>21)</sup> , , Tucci <sup>26)</sup> vala-  
 . Pentoxyphyline 400 cyclovir 가  
 , 10% low molecular  
 mg 1 3 , 3~7  
 weight dextran 500 mL 1 4 5,000~  
 heparin 12 2~3  
 10,000 unit 가  
 triiodinated benzoic acid diatrizoate  
 (Hypaque)가 가  
 diatrizoate 54%가  
 19% .<sup>22)</sup> Diatrizoate  
 . Fisch <sup>18)</sup> papaverine dextran

**면역억제제**

antibodies)가 (cross - reacting 가 가 . Yeo 28)29) . glucocorticoid, (cytotoxic 가 agent) 가 Wilkins 17) , carbogen , “shotgun regimen ” 1/3 1/3 40~60 dB 30) 47~63% 가 가 가 40 2 1 6 30)

**중심 단어 :**

**REFERENCES**

- 1) Hughes GB, Barna BP, Kinney SE, Calabrese LH, Nalepa NJ. *Clinical diagnosis of immune inner ear disease. Laryngoscope* 1988;98:251-3.
- 2) Kanzaki J, Toshiaki O. *Steroid-responsive bilateral sensorineural hearing loss and immune complexes. Arch Otorhinolaryngol* 1981;230:5-9.
- 3) McCabe BF. *Autoimmune inner ear disease: therapy. Am J Otol* 1989;10:196-7.
- 4) Harris JP. *Immunologic mechanisms in disorders of the inner ear. In Cummings CW, Their SO, editors, Otolaryngology-Head and Neck Surgery, 2nd ed., Mosby Year Book Inc.; 1994. p.2926-42.*
- 5) Harris JP. *Immunologic disorders affecting the ear. In Cummings CW, Their SO, editors, Otolaryngology-Head and Neck Surgery, 2nd ed., Mosby Year Book Inc.;1998. p.3172-85.*
- 6) Kennedy MS, Domen RE. *Therapeutic apheresis: application and future directions. Vox Sang* 1983;45:261-77.
- 7) Silvergleid AJ. *Applications and limitations of hemapheresis. Annu Rev Med* 1983;34:69-89.
- 8) Luetje CM, Berliner K. *Plasmapheresis in autoimmune inner ear disease: long-term follow-up. Am J Otol* 1997;18:572-6.
- 9) Sismanis A, Wise CM, Johnson GD. *Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg* 1977;116:146-52.
- 10) Metteson EL, Fabry DA, Facer GW, Beatty CW, Driscoll CW, Strome SE, McDonald TJ. *Open trial of methotrexate as treatment for autoimmune hearing loss. Arthritis Care Research* 2001;45:146-50.
- 11) Morgan SL, Baggot JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcon GS. *The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum* 1990;33:9-18.
- 12) Steinman L. *Autoimmune Disease. Scientific American* 1993; 269:107-14.
- 13) Dalal M, Kim S, Vaskuhl R. *Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol* 1997;159:3-6.
- 14) Yeo SW, Chang KH, Park SN, Suh BD. *Effects of testosterone in the treatment of immune-mediated hearing loss. Eur Arch Oto-Rhino-Laryngol* 2003;260:316-9.
- 15) Wilson WR, Byl FM, Laird N. *The efficacy of steroids in the treatment of idiopathic sudden hearing loss: A double-blind clinical study. Arch Otorhinolaryngol* 1980;106:772-6.
- 16) Moskowitz D, Lee KJ, Smith HW. *Steroid use in idiopathic sudden sensorineural hearing loss. Laryngoscope* 1984;94:664-6.
- 17) Wilkins SA Jr, Mattox DE, Lyles A. *Evaluation of a “shotgun” regimen for sudden hearing loss. Otolaryngol Head Neck Surg* 1987;97:474-80.
- 18) Fisch U. *Management of sudden deafness. Otolaryngol Head Neck Surg* 1983;91:3-8.
- 19) Donaldson JA. *Heparin therapy for sudden sensorineural hearing loss. Arch Otorhinolaryngol* 1979;105:351-2.
- 20) Rahko T, Kotti V. *Comparison of carbogen inhalation and intravenous heparin infusion therapies in idiopathic sudden sensorineural hearing loss. Acta Otolaryngol (Stockh)* 1997;

- :
- Suppl 529:86-7.*
- 21) Hulterantz E, Stenquist M, Lyttkens L. *Sudden deafness: a retrospective evaluation of dextran therapy. ORL J Otorhinolaryngol Relat Spec 1994;56:137-42*
  - 22) Morimitsu T. *Dysfunction of stria vascularis as a new theory of sudden deafness. Adv Otorhinolaryngol 1977;22:57-75.*
  - 23) Redleaf MI, Bauer CA, Gantz BJ, Hoffman HT, McCabe BF. *Diatrizoate and dextran treatment of sudden sensorineural hearing loss. Am J Otol 1995;16:295-303.*
  - 24) Schknecht HF, Donovan ED. *The pathology of idiopathic sudden sensorineural hearing loss. Arch Otorhinolaryngol 1986;243:1-15.*
  - 25) Wilson WR. *The relationship of the herpesvirus family to sudden hearing loss: a prospective clinical study and literature review. Laryngoscope 1986;96:870-7.*
  - 26) Tucci DL, Farmer JC Jr, Kitch RD, Witsell DL. *Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir. Otol Neurotol 2002;23:301-8.*
  - 27) Hughes GB. *Sudden sensorineural hearing loss. Otolaryngol Clin North Am 1996;29:393-413.*
  - 28) Yeo SW, Chang KH, Suh BD, Kim TG, Han H. *Distribution of HLA-A, -B and -DRB1 alleles in patients with sudden sensorineural hearing loss. Acta Otoaryngologica (Stockh). 2000;120:710-5.*
  - 29) Yeo SW, Park SN, Park YS, Suh BD, Han H, Choi HB, Kim TG. *Different distribution of HLA class II alleles according to response to steroid therapy in sudden sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 2001;127:945-9.*
  - 30) Yoon TH, Paparella MM, Schachern PA, Alleva M. *Histopathology of sudden hearing loss. Laryngoscope 1990;100:707-15.*